By Denny Jacob International stocks trading in New York closed lower on Friday. The S&P/BNY Mellon index of American depositary receipts edged down 0.8% to...
AstraZeneca CEO Pascal Soriot reportedly thinks that Covid-19 booster shots for young and healthy people may not be wise. Soriot told the UK Telegraph research suggests that vaccines give healthy people protection against severe disease for a
Japan’s health ministry said on Monday that its panel of experts had agreed to approve manufacturing and sales of AstraZeneca’s COVID-19 preventive treatment Evusheld.
The new data position AstraZeneca to significantly expand use of Farxiga in heart failure and compete with Lilly and Boehringer Ingelheim’s rival drug Jardiance.
Study is result of collaboration between Sheikh Khalifa Medical City and AstraZeneca
/PRNewswire/ -- The “Gynecological Cancer Drugs Market By Therapeutic Modality, By Indication: Global Opportunity Analysis and Industry Forecast, 2020-2030”...
Monday’s top analyst upgrades and downgrades included Affirm, AstraZeneca, Broadcom, Centene, Dell Technologies, Dollar General, Marvell Technology, Medical Properties Trust, Tesla, Ulta Beauty, Union Pacific and Workday.
The global smart inhalers market size was US$ 147.7 million in 2021. The global smart inhalers marke
Three and a half months after teasing a topline win for its heart failure and type 2 diabetes med Farxiga, AstraZeneca laid out the details of the drug’s performance in another heart failure patient population to a crowd at the European Society of Cardiology Congress. The UK Big
Custom Pre-earnings Bullish Diagonal Trigger in AstraZeneca PLC (NASDAQ:AZN) Earnings.
Situation Report in English on Nigeria about Health, Protection and Human Rights, Epidemic and more; published on 27 Aug 2022 by Govt. Nigeria, Health Cluster and 2count other organizations
AstraZeneca has received the Japan’s MHLW approval for Ultomiris (ravulizumab) to treat generalised myasthenia gravis (gMG) in adult patients.
Why is the AstraZeneca share price outperforming its rivals GlaxoSmithKline and PureTech Health? Read our biopharma news update.
(Reuters) - The COVAX facility, backed by the World Health Organization (WHO) and the Global Alliance for Vaccines and Immunization (GAVI), has delive...
Thai drugmaker Siam Bioscience, owned by the country’s king, reported a near 50-fold increase in annual profit in 2021, when it began producing AstraZeneca Plc’s COVID-19 vaccine, government data shows.
AstraZeneca announces three new drug approvals in Japan
...
By Denny Jacob International stocks trading in New York closed mixed on Wednesday. The S&P/BNY Mellon index of American depositary receipts ticked up 0.2% to...
Analysts at JP Morgan reiterated their underweight stance on Hargreaves Lansdown due to the combination of their forecasts for a drop in UK gross domestic product in 2023, alongside “elevated” inflation and the rise in overall living costs, amongst other factors.